Skip to main content

Table 2 The association between pCR or non-pCR status and clinical features

From: Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

 

pCR (n) (%)

non-pCR (n) (%)

P value

BMI

  

0.136

 Underweight,

3 (33.3)

6 (66.7)

 

 Normal weight

22 (50.0)

22 (50.0)

 

 Overweight

2 (18.2)

9 (81.8)

 

ECOG-PS

  

0.432

 0

7 (35.0)

13 (65.0)

 

 1

20 (45.5)

24 (54.5)

 

Clinical stage

  

0.742

 II

9 (47.4)

10 (52.6)

 

 III

14 (42.4)

19 (57.6)

 

 IV

4 (33.3)

8 (66.7)

 

Tumor site

  

0.945

 Upper

1 (33.3)

2 (66.7)

 

 Middle

13 (43.3)

17 (56.7)

 

 Lower

13 (41.9)

18 (58.1)

 
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us